Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor

Roberta Riccioni, Daniela Diverio, Viviana Riti, Sonia Buffolino, Gualtiero Mariani, Alessandra Boe, Michele Cedrone, Tiziana Ottone, Robin Foà, Ugo Testa

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The common beta chain subunit (βc), also known as CDw131, shared by the interleukin-3 (IL-3), granulocytic macrophage colony-stimulating factor (GM-CSF) and IL-5 receptors, is required for high-affinity ligand binding and signal transduction. The present study explored the expression of CDw131 in 105 de novo cases of acute myeloid leukaemia (AML). The levels of CDw131 expression were used to identify two AML subgroups characterized by low (75/105) and high (30/105) expression of this receptor chain. It was observed that (i) the level of CDw131 expression strictly correlated with the level of CD116 (GM-CSFα receptor chain) and CD123 (IL-3Rα chain); (ii) AMLs with high CDw131 expression were characterized by low CD34 expression and usually high CD11b, CD14 expression; (iii) AMLs with high CDw131 expression frequently co-expressed receptors for angiogenic growth factors (vascular endothelial growth factor R2, Tie-2); (iv) AMLs with high CDw131 expression were more cycling than those with low CDw131 expression; (v) AMLs with high CDw131 frequently displayed Feline Murine Sarcoma (FMS-related) tyrosine kinase 3 (FLT3) internal tandem duplication and constitutively activated Signal Transducer and Activator of Transcription-5 (STAT5). In conclusion, the analysis of the level of CDw131 expression enabled the identification of a subset of AMLs characterized by a high cycling status, the expression of myelo-monocytic markers, mutated FLT3 and the co-expression of receptors for angiogenic growth factors. These findings are of value for the development of new therapeutic strategies for the treatment of these AMLs.

Original languageEnglish
Pages (from-to)376-387
Number of pages12
JournalBritish Journal of Haematology
Volume144
Issue number3
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Interleukin-5 Receptor alpha Subunit
Angiogenesis Inducing Agents
Interleukin-3
Receptor Protein-Tyrosine Kinases
Granulocyte-Macrophage Colony-Stimulating Factor
Acute Myeloid Leukemia
Interleukin-5 Receptors
Macrophage Colony-Stimulating Factor Receptors
STAT5 Transcription Factor
Macrophage Colony-Stimulating Factor
Interleukins
Felidae
Growth
Sarcoma
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Signal Transduction
Ligands
Therapeutics

Keywords

  • Granulo-monocytic colony stimulating factor
  • Growth factor receptors
  • Interleukin-3
  • Leukaemia
  • Mutations

ASJC Scopus subject areas

  • Hematology

Cite this

Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. / Riccioni, Roberta; Diverio, Daniela; Riti, Viviana; Buffolino, Sonia; Mariani, Gualtiero; Boe, Alessandra; Cedrone, Michele; Ottone, Tiziana; Foà, Robin; Testa, Ugo.

In: British Journal of Haematology, Vol. 144, No. 3, 02.2009, p. 376-387.

Research output: Contribution to journalArticle

Riccioni, Roberta ; Diverio, Daniela ; Riti, Viviana ; Buffolino, Sonia ; Mariani, Gualtiero ; Boe, Alessandra ; Cedrone, Michele ; Ottone, Tiziana ; Foà, Robin ; Testa, Ugo. / Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. In: British Journal of Haematology. 2009 ; Vol. 144, No. 3. pp. 376-387.
@article{24f3ca76b2804ae1a3464e370fd7d981,
title = "Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor",
abstract = "The common beta chain subunit (βc), also known as CDw131, shared by the interleukin-3 (IL-3), granulocytic macrophage colony-stimulating factor (GM-CSF) and IL-5 receptors, is required for high-affinity ligand binding and signal transduction. The present study explored the expression of CDw131 in 105 de novo cases of acute myeloid leukaemia (AML). The levels of CDw131 expression were used to identify two AML subgroups characterized by low (75/105) and high (30/105) expression of this receptor chain. It was observed that (i) the level of CDw131 expression strictly correlated with the level of CD116 (GM-CSFα receptor chain) and CD123 (IL-3Rα chain); (ii) AMLs with high CDw131 expression were characterized by low CD34 expression and usually high CD11b, CD14 expression; (iii) AMLs with high CDw131 expression frequently co-expressed receptors for angiogenic growth factors (vascular endothelial growth factor R2, Tie-2); (iv) AMLs with high CDw131 expression were more cycling than those with low CDw131 expression; (v) AMLs with high CDw131 frequently displayed Feline Murine Sarcoma (FMS-related) tyrosine kinase 3 (FLT3) internal tandem duplication and constitutively activated Signal Transducer and Activator of Transcription-5 (STAT5). In conclusion, the analysis of the level of CDw131 expression enabled the identification of a subset of AMLs characterized by a high cycling status, the expression of myelo-monocytic markers, mutated FLT3 and the co-expression of receptors for angiogenic growth factors. These findings are of value for the development of new therapeutic strategies for the treatment of these AMLs.",
keywords = "Granulo-monocytic colony stimulating factor, Growth factor receptors, Interleukin-3, Leukaemia, Mutations",
author = "Roberta Riccioni and Daniela Diverio and Viviana Riti and Sonia Buffolino and Gualtiero Mariani and Alessandra Boe and Michele Cedrone and Tiziana Ottone and Robin Fo{\`a} and Ugo Testa",
year = "2009",
month = "2",
doi = "10.1111/j.1365-2141.2008.07491.x",
language = "English",
volume = "144",
pages = "376--387",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor

AU - Riccioni, Roberta

AU - Diverio, Daniela

AU - Riti, Viviana

AU - Buffolino, Sonia

AU - Mariani, Gualtiero

AU - Boe, Alessandra

AU - Cedrone, Michele

AU - Ottone, Tiziana

AU - Foà, Robin

AU - Testa, Ugo

PY - 2009/2

Y1 - 2009/2

N2 - The common beta chain subunit (βc), also known as CDw131, shared by the interleukin-3 (IL-3), granulocytic macrophage colony-stimulating factor (GM-CSF) and IL-5 receptors, is required for high-affinity ligand binding and signal transduction. The present study explored the expression of CDw131 in 105 de novo cases of acute myeloid leukaemia (AML). The levels of CDw131 expression were used to identify two AML subgroups characterized by low (75/105) and high (30/105) expression of this receptor chain. It was observed that (i) the level of CDw131 expression strictly correlated with the level of CD116 (GM-CSFα receptor chain) and CD123 (IL-3Rα chain); (ii) AMLs with high CDw131 expression were characterized by low CD34 expression and usually high CD11b, CD14 expression; (iii) AMLs with high CDw131 expression frequently co-expressed receptors for angiogenic growth factors (vascular endothelial growth factor R2, Tie-2); (iv) AMLs with high CDw131 expression were more cycling than those with low CDw131 expression; (v) AMLs with high CDw131 frequently displayed Feline Murine Sarcoma (FMS-related) tyrosine kinase 3 (FLT3) internal tandem duplication and constitutively activated Signal Transducer and Activator of Transcription-5 (STAT5). In conclusion, the analysis of the level of CDw131 expression enabled the identification of a subset of AMLs characterized by a high cycling status, the expression of myelo-monocytic markers, mutated FLT3 and the co-expression of receptors for angiogenic growth factors. These findings are of value for the development of new therapeutic strategies for the treatment of these AMLs.

AB - The common beta chain subunit (βc), also known as CDw131, shared by the interleukin-3 (IL-3), granulocytic macrophage colony-stimulating factor (GM-CSF) and IL-5 receptors, is required for high-affinity ligand binding and signal transduction. The present study explored the expression of CDw131 in 105 de novo cases of acute myeloid leukaemia (AML). The levels of CDw131 expression were used to identify two AML subgroups characterized by low (75/105) and high (30/105) expression of this receptor chain. It was observed that (i) the level of CDw131 expression strictly correlated with the level of CD116 (GM-CSFα receptor chain) and CD123 (IL-3Rα chain); (ii) AMLs with high CDw131 expression were characterized by low CD34 expression and usually high CD11b, CD14 expression; (iii) AMLs with high CDw131 expression frequently co-expressed receptors for angiogenic growth factors (vascular endothelial growth factor R2, Tie-2); (iv) AMLs with high CDw131 expression were more cycling than those with low CDw131 expression; (v) AMLs with high CDw131 frequently displayed Feline Murine Sarcoma (FMS-related) tyrosine kinase 3 (FLT3) internal tandem duplication and constitutively activated Signal Transducer and Activator of Transcription-5 (STAT5). In conclusion, the analysis of the level of CDw131 expression enabled the identification of a subset of AMLs characterized by a high cycling status, the expression of myelo-monocytic markers, mutated FLT3 and the co-expression of receptors for angiogenic growth factors. These findings are of value for the development of new therapeutic strategies for the treatment of these AMLs.

KW - Granulo-monocytic colony stimulating factor

KW - Growth factor receptors

KW - Interleukin-3

KW - Leukaemia

KW - Mutations

UR - http://www.scopus.com/inward/record.url?scp=58449106592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449106592&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2008.07491.x

DO - 10.1111/j.1365-2141.2008.07491.x

M3 - Article

VL - 144

SP - 376

EP - 387

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -